PATENT CLAIM ANALYSIS

Application Number: 15891466
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-08
Patent Classification: ["424", "133100"]

Abstract:
A recombinant human monoclonal pentameric IgM antibody comprising the capability of oligospecific binding to purified ganglioside epitopes GD3, GM3, GD2 and GM1 and the capability of specific binding to malignant cancer cells selected from the group consisting of melanoma cells, small cell lung cancer cells, glioblastoma cells, and estrogen receptor-negative metastatic breast cancer cells; a cell line producing the IgM antibody; and the use of the IgM antibody as a diagnostic tool and/or as a therapeutic agent.

Claim (Index 21):
The IgM antibody of  claim 6 , in essentially a pentameric isoform.

Metadata:
- Claim Count in Document: 12.0
- Percentile: 88.0
- Lexical Diversity: 1.63462
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['12494631', '13933594', '13593057', '13510270', '12445071']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.682029265420212
- 35 USC 102 Novelty (BERT): 0.5272401676194954
- Combined Prediction Score: 0.6665503556401404
- Mean Citation Score: 302.419756
- Max Citation Score: 331.21426
- Similarity Product: 219.1359916797078

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test